Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
|Articles|August 1, 2003
Ms.Codit
Author(s)Inga Ellzey
Q: As HIPAA moves ahead at full speed, it has brought my attention to many other issues in our practice ?? among them chart audits. We have four physicians and two physician assistants in our practice. I plan to perform chart audits personally but don't know where to start. How do I get started?
Advertisement
Advertisement
Related to this article
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
3
North Immunology, Aethlon Merge to Advance NOR-101 for AD
4
Diagnostic Delays and the Psychosocial Burden of HS
5